RxDoctor Payments Data

Mark Passarella, MD

Urology · Charlottesville, VANPI 1841279445

Payments from drug & device makers

$12,085in general payments, 2019–2025

Across 474 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • AbbVie$886
  • Dendreon Pharmaceuticals LLC$735
  • Astellas Pharma US Inc$689
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$1,30211%
  • Food & beverage$10,66888%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,085 in reported general payments places this provider in the 75th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$488,516
Medicare patients
1,179
Services billed
12,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix29$75,999
MyrbetriqMirabegron75$53,791
Tamsulosin Hcl573$8,444
Dutasteride302$7,590
Tolterodine Tartrate ErTolterodine Tartrate23$4,595
Finasteride305$4,101
Tadalafil15$3,666
Testosterone12$3,026
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$2,023
Silodosin23$1,559
Potassium Citrate ErPotassium Citrate13$1,040
Bicalutamide20$937
Cephalexin127$621
Oxybutynin Chloride ErOxybutynin Chloride13$404
Terazosin Hcl12$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$508$75,99929 claims
Astellas Pharma US IncMyrbetriq$689$53,79175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 300 urology providers in Virginia.

Other urology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →